Patents by Inventor Lina Yu

Lina Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11980681
    Abstract: The invention relates to a dentin collagen fibril demineralizing material, and a preparation method and application thereof. The invention relates to a conjugate of water-soluble chitosan and an aminocarboxylic acid metal chelating agent used for dental demineralization, preferably dentin demineralization. The invention also discloses a dentin collagen fibril demineralizing material and a preparation method and application thereof, wherein the material is prepared from 0.5-1 part by mass of water-soluble chitosan, 10-30 parts by mass of EDTA, and 0.8-1.5 parts by mass of cross-linking agent. The invention relates to a dental demineralization composition comprising a conjugate and a material of the invention. The conjugate, material and composition can be used for dentin demineralization treatment before dental bonding and restoration.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: May 14, 2024
    Assignee: The Fourth Military Medical University of Chinese People's Liberation Army
    Inventors: Lina Niu, Jihua Chen, Zhiming Zheng, Jingmei Guo, Fan Yu, Kai Jiao
  • Patent number: 11977788
    Abstract: The present disclosure provides a network connection configuration method and an apparatus thereof.
    Type: Grant
    Filed: June 16, 2023
    Date of Patent: May 7, 2024
    Assignee: Zhuhai Pantum Electronics Co., Ltd.
    Inventors: Yinggui Chen, Zongxin Yang, Yongjiu Jiang, Han Yu, Lina Meng
  • Publication number: 20240131017
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Application
    Filed: December 29, 2023
    Publication date: April 25, 2024
    Applicant: Techfields Pharma Co., Ltd.
    Inventors: Chongxi Yu, Lina Xu
  • Publication number: 20240122956
    Abstract: The present disclosure relates to the field of medicine and specifically to an application of naringin combined with rapamycin in preparation of medications for treating hyperlipidemia. Naringin achieves anti-inflammatory and lipid-lowering effects by inhibiting the formation of oxLp-NLRP3 complexes. The present disclosure has been substantiated through cellular experiments and animal experiments, it demonstrates that naringin effectively intervenes in the early progression of hyperlipidemia by neutralizing oxLp and inhibiting the formation of oxLp-NLRP3 complexes. The inhibitory effect of naringin on oxLp-NLRP3 complexes contributes to unleashing the therapeutic potential of rapamycin in hyperlipidemia, providing a combined strategy for the prevention and treatment of hyperlipidemia-related diseases in clinical applications.
    Type: Application
    Filed: December 28, 2023
    Publication date: April 18, 2024
    Applicant: AIR FORCE MEDICAL UNIVERSITY
    Inventors: Lina Niu, Kaiyan Wang, Weiwei Yu, Wen Qin, Yuxuan Ma, Chen Lei
  • Publication number: 20240115562
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Application
    Filed: November 13, 2023
    Publication date: April 11, 2024
    Applicant: Techfields Pharma Co., Ltd.
    Inventors: Chongxi Yu, Lina Xu
  • Publication number: 20220283182
    Abstract: A kit and a method for combined detection of PCT and Presepsin in a sample to be tested, and use thereof. The kit comprises: a capture antibody mixture, the capture antibody mixture comprising a procalcitonin capture antibody coated on a solid phase and a soluble CD14 subtype capture antibody coated on a solid phase; and a detection antibody mixture, the detection antibody mixture comprising a labeled procalcitonin detection antibody and a labeled soluble CD14 subtype detection antibody. The kit, method and use thereof can detect a combined signal value of PCT and Presepsin in a sample in a reaction system, the comparison between the combined signal value and a reference value can be used for evaluating the possibility of a patient suffering from sepsis and evaluating the prognosis of a suspected sepsis patient, and compared with detecting PCT or Presepsin in a sample alone, a more efficient diagnosis and a better prognostic power are provided.
    Type: Application
    Filed: May 18, 2022
    Publication date: September 8, 2022
    Inventors: Lina YU, Ke LI, Jianwen HE
  • Publication number: 20220256860
    Abstract: Disclosed in the present invention is a biological preparation and application thereof, relates to the technical field of microorganisms, which includes a bacterial suspension or an anaculture or a crude extract or an extracellular metabolite of Burkholderia latens, wherein the Burkholderia latens is Burkholderia latens G12, preserved in CGMCC (No. 20817), the present invention has a good inhibition effect on Fusarium graminearum and Aspergillus flavus, and the infection with the Fusarium graminearum or Aspergillus flavus on the grains of the wheat or peanut in a storage period can be obviously reduced, and the storage period of the wheat or peanut can be prolonged. In addition, the present invention has a good degradation effect on aflatoxin.
    Type: Application
    Filed: March 3, 2021
    Publication date: August 18, 2022
    Inventors: Jie SUN, Mingqing WANG, Chushu ZHANG, Lina YU, Jie BI, Yu SONG, Jiancheng ZHANG, Qingli YANG
  • Patent number: 9910589
    Abstract: A virtual keyboard with dynamically adjusted recognition zones for predicted user-intended characters. When a user interaction with the virtual keyboard is received on the virtual keyboard, a character in a recognition zone encompassing the detected interaction location is selected as the current input character. Characters likely to be the next input character are predicted based on the current input character. The recognition zones of the predicted next input characters are adjusted to be larger than their original sizes.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: March 6, 2018
    Assignee: Nvidia Corporation
    Inventors: Zhen Jia, Jing Guo, Lina Yu, Yuqi Cui
  • Publication number: 20150128083
    Abstract: A virtual keyboard with dynamically adjusted recognition zones for predicted user-intended characters. When a user interaction with the virtual keyboard is received on the virtual keyboard, a character in a recognition zone encompassing the detected interaction location is selected as the current input character. Characters likely to be the next input character are predicted based on the current input character. The recognition zones of the predicted next input characters are adjusted to be larger than their original sizes.
    Type: Application
    Filed: October 30, 2014
    Publication date: May 7, 2015
    Inventors: Zhen Jia, Jing Guo, Lina Yu, Yuqi Cui